Guardant Health licenses genomic cancer assays to Adicon

Guardant Health has announced a strategic partnership with Chinese clinical laboratory firm Adicon to license its comprehensive genomic profiling (CGP) tests to accelerate the development of new cancer therapies in the country.

The collaboration will provide biopharmaceutical firms with access to Guardant Health’s cancer tests portfolio, which will help advance their clinical trial and drug development programs.

Under the deal, Guardant Health will grant a license for Adicon to use its Guardant360 and GuardantOMNI tests, as well as Guardant360 TissueNext, a tissue-based biopsy for any solid cancerous tumor patients.

These tests will allow researchers to identify patients with cancers that have the appropriate molecular profile for their clinical programs.

They will also facilitate patient screening, clinical trial enrollment and the providing of information regarding patient response, tumor evolution and resistance.

Additionally, biopharmaceutical firms will have access to Guardant Reveal, which is said to be the first blood-only test for detecting residual disease and monitoring cancer recurrence for early-stage cancer research and development.

Guardant Health co-CEO Helmy Eltoukhy said: “Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China.

“With Adicon’s extensive expertise in clinical laboratory services, we believe they are the ideal partner to help biopharmaceutical companies bring the next generation of cancer therapies to patients in the region.”

The company’s screening portfolio also includes the Shield test, which has been commercially launched and aims to address the needs of individuals that are eligible for cancer screening.

Last May, Guardant Health reported that its Guardant Reveal blood-only liquid biopsy test was able to identify patients with stage I-IV colorectal cancer (CRC) with increased risk of recurrence.

Related Companies

Leave a Comment

Your email address will not be published.